Johnson & Johnson to present 25 abstracts on Generalized Myasthenia Gravis at AANEM and MGFA 2024, featuring promising nipocalimab data
Johnson & Johnson announced that 25 abstracts featuring robust research to understand unmet needs in generalized myasthenia gravis (gMG) and evaluate nipocalimab as a potential advanced treatment option… read more.
